Keros Therapeutics (KROS) Net Cash Flow (2019 - 2025)

Keros Therapeutics (KROS) has 7 years of Net Cash Flow data on file, last reported at -$406.1 million in Q4 2025.

• For the quarter ending Q4 2025, Net Cash Flow fell 1488.37% year-over-year to -$406.1 million; the trailing twelve-month figure through Dec 2025 stood at -$272.5 million (down 218.99% YoY), and the FY2025 full-year result was -$272.5 million, down 218.99% from the prior year.
• Net Cash Flow for Q4 2025 stood at -$406.1 million, down from $3.3 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $160.6 million in Q1 2025 and bottomed at -$406.1 million in Q4 2025.
• The 5-year median for Net Cash Flow is $900500.0 (2022), against an average of $1.1 million.
• The widest annual swing landed in 2023, when Net Cash Flow jumped 5071.22%; it then plunged 1488.37% in 2025.
• A 5-year view of Net Cash Flow shows it stood at $8.7 million in 2021, then soared by 355.84% to $39.6 million in 2022, then increased by 9.17% to $43.3 million in 2023, then tumbled by 32.38% to $29.2 million in 2024, then slumped by 1488.37% to -$406.1 million in 2025.
• The last three Net Cash Flow figures came in at -$406.1 million (Q4 2025), $3.3 million (Q3 2025), and -$30.3 million (Q2 2025), per Business Quant data.

Peer Comparison